These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 12638361)
1. [Efficacy of the heptavalent pneumococcal vaccine against meningitis, pneumonia and acute otitis media in pediatric age. Theoretical coverage offered by the heptavalent conjugate vaccine in Italy]. Principi N; Esposito S Ann Ig; 2002; 14(6 Suppl 7):21-30. PubMed ID: 12638361 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. Eskola J; Kilpi T; Palmu A; Jokinen J; Haapakoski J; Herva E; Takala A; Käyhty H; Karma P; Kohberger R; Siber G; Mäkelä PH; N Engl J Med; 2001 Feb; 344(6):403-9. PubMed ID: 11172176 [TBL] [Abstract][Full Text] [Related]
4. [Value of pneumococcal vaccination in infants and young children]. Adam D; Scholz H Klin Padiatr; 2001; 213(3):109-13. PubMed ID: 11417363 [TBL] [Abstract][Full Text] [Related]
5. Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine. Garbutt J; Rosenbloom I; Wu J; Storch GA Pediatrics; 2006 Jun; 117(6):e1087-94. PubMed ID: 16740811 [TBL] [Abstract][Full Text] [Related]
6. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use. Toltzis P; Jacobs MR Infect Dis Clin North Am; 2005 Sep; 19(3):629-45. PubMed ID: 16102653 [TBL] [Abstract][Full Text] [Related]
7. [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine]. de Arístegui Fernández J; Corretger Rauet JM; García Martín F; Hernández-Sampelayo T; Moraga Llop FA; Rodrigo Gonzalo De Liria C; Ruiz Contreras J; An Esp Pediatr; 2002 Jan; 56(1):79-90. PubMed ID: 11792258 [TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH; Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958 [TBL] [Abstract][Full Text] [Related]
9. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612 [TBL] [Abstract][Full Text] [Related]
10. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. Shields B J Pediatr Health Care; 2001; 15(4):203-8; quiz 209-10. PubMed ID: 11462129 [No Abstract] [Full Text] [Related]
12. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975 [TBL] [Abstract][Full Text] [Related]
13. [Medical indications and effectiveness of the pneumococcal conjugate vaccine]. Reinert RR Laryngorhinootologie; 2006 Apr; 85(4):291-8; quiz 299-300. PubMed ID: 16615030 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089 [TBL] [Abstract][Full Text] [Related]
15. [Epidemiology of meningitis, pneumonia and acute otitis due to Streptococcus pneumoniae in pediatric in Italy]. Esposito S; Principi N Ann Ig; 2002; 14(6 Suppl 7):7-16. PubMed ID: 12638359 [TBL] [Abstract][Full Text] [Related]
16. New vaccines against otitis media: projected benefits and cost-effectiveness. O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754 [TBL] [Abstract][Full Text] [Related]
17. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Cohen R; Levy C; de La Rocque F; Gelbert N; Wollner A; Fritzell B; Bonnet E; Tetelboum R; Varon E Pediatr Infect Dis J; 2006 Nov; 25(11):1001-7. PubMed ID: 17072121 [TBL] [Abstract][Full Text] [Related]
18. Heptavalent pneumococcal conjugate vaccine: current and future impact. Hsu KK; Pelton SI Expert Rev Vaccines; 2003 Oct; 2(5):619-31. PubMed ID: 14711324 [TBL] [Abstract][Full Text] [Related]
19. [Antipneumococcal vaccine: up date and prospective]. Caramia G; Pastorelli G Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607 [TBL] [Abstract][Full Text] [Related]
20. Pneumococcal serogroups and serotypes in severe pneumococcal pneumonia in Belgian children: theoretical coverage of the 7-valent and 9-valent pneumococcal conjugate vaccines. De Schutter I; Malfroot A; Piérard D; Lauwers S Pediatr Pulmonol; 2006 Aug; 41(8):765-70. PubMed ID: 16779850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]